What indicators are likely to stimulate the Controlled Release Drug Delivery market?

The global control release drug delivery market was valued at USD 47.39 billion in 2021 and is anticipated to expand at a CAGR of 10.5% over the forecast period. Changing prescription patterns of physicians preferring controlled release drug delivery over conventional systems owing to the benefits such as high-therapeutic efficacy, better patient compliance, and reduced treatment cost are expected to contribute towards the growth of the market over the forecast period. Moreover, being a part of a highly competitive and fragmented market, pharmaceutical companies are pro-active with the changing market requirements and are continuously investing on developing controlled release drug delivery system, thereby significantly driving the demand.

Gather more insights about the market drivers, restrains and growth of the Global Controlled Release Drug Delivery Market

Constantly rising R&D expenditure by pharmaceutical development companies that are focused on the development of efficient therapy for chronic and non-communicable complications such as cancer, diabetes, and hypertension are expected to boost the market growth over the forecast period. For instance, Taris an R&D-based biomedical company’s pipeline product TAR-200 (Gemcitabine) indicated for the treatment of bladder cancer includes a controlled release drug delivery system. Furthermore, in 2019, Johnson & Johnson completed the acquisition of Taris Biomedical. Its lead investigational product TAR-200 is reported to be one of the main reasons behind the acquisition.

The rising geriatric and pediatric population globally is one of the major factors contributing to the market growth, largely due to the non-adherence to the medication regimen as it is very common among these age groups. Geriatric populations suffer from compromised physical, mental, and biological functions that affect their medicine intake. Also, their body cannot tolerate high doses and harsh side effects of drugs. Thus, the demand for controlled release drug delivery systems is expected to grow with the steeply rising patient population.

Controlled release drug delivery allows a significant reduction in dose and dosage frequency, prevents abnormal fluctuations of plasma drug levels, improves efficacy, enhances patient compliance, and achieves uniform drug effects of the administered drug. In comparison to traditional delivery systems, the control releases drug delivery systems achieve a prolonged therapeutic effect, delivering drugs at the target site at a pre-determined that too at a predictable drug release kinetics. Thus, with several added benefits offered by the controlled release delivery system, their adoption is expected to increase at a notable rate over the forecast period.

Browse through Grand View Research's Healthcare Industry Related Reports

• Injectable Drug Delivery Market - The injectable drug delivery (IDD) market was estimated at USD 331.0 billion in 2015. With an upsurge in the number of chronic diseases like diabetes and cancer, the need for drug delivery systems has risen substantially.
• Microencapsulation Market - The global microencapsulation market size was valued at USD 7.88 billion in 2018 and is expected to register a CAGR of 13.7% over the forecast period. Rising acceptance of microencapsulated materials in the food and beverage, pharmaceutical, and agrochemical industries is expected to have a positive impact on the growth.

Controlled Release Drug Delivery Market Segmentation

Grand View Research has segmented the global controlled release drug delivery market on the basis of technology, release mechanism, application, and region:

• Technology Outlook (Revenue in USD Million, 2018 - 2030)

o   Wurster Technique

o   Coacervation

o   Micro Encapsulation

o   Implants

o   Transdermal

o   Targeted Delivery

o   Others (Microelectromechanical Technology, Liposomes)

• Release Mechanism Outlook (Revenue, USD Million, 2018 - 2030)

o   Polymer Based Systems

o   Micro Reservoir Partition Controlled Drug Delivery Systems

o   Feedback Regulated Drug Delivery Systems

o   Activation-modulated Drug Delivery Systems

• Osmotic Pressure Activated
• Hydrodynamic Pressure Activated
• Vapor Pressure Activated
• Mechanically Activated
• Magnetically Activated

o   Chemically Activated

• pH Activated
• Hydrolysis Activated
• Enzyme Activated
• Application Outlook (Revenue, USD Million; 2018 - 2030)

o   Metered Dose Inhalers

o   Injectable

o   Transdermal and Ocular Patches

o   Infusion Pumps

o   Oral Controlled-drug delivery Systems

o   Drug Eluting Stents

• Controlled Release Drug Delivery Regional Outlook (Revenue, USD Million, 2017 - 2030)

o   North America

o   Europe

o   Asia Pacific

o   Latin America

o   Middle East & Africa

Market Share Insights

January 2016: Capsugel announced the completion of the acquisition of Xcelience and Powdersize, which aided the company to expand its existing resources with respect to its dosage form solutions business segment.

October 2015: Capsugel announced the launch of enTRinsic drug delivery technology that provides complete enteric protection along with targeted release into the upper gastrointestinal tract for a variety of compounds.

Key Companies profiled:

Some prominent players in the global Controlled Release Drug Delivery market include

• Orbis Biosciences, Inc.
• Merck and Co., Inc.
• Alkermesplc
• Johnson and Johnson
• Coating Place, Inc.
• Corium International, Inc.
• Depomed, Inc.
• Pfizer, Inc.
• Aradigm Corporation
• Capsugel

Order a free sample PDF of the Controlled Release Drug Delivery Market Intelligence Study, published by Grand View Research.